Story

Sono-Tek Shares Rise on Record $3.6 Million Medical Device Production Line Order

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Sono-Tek Shares Rise on Record $3.6 Million Medical Device Production Line Order
Text size
Background

Sono-Tek Corporation (NASDAQ: SOTK) shares gained in premarket trading after the company announced it received a record $3.6 million purchase order for a single integrated production line. The order from an existing customer is for an advanced manufacturing system to be used in the production of medical diagnostic devices.

Order Details and Significance

The company stated that the $3.6 million deal represents the largest order in its history for one integrated production line. While some previous orders had higher total values, Sono-Tek clarified those were comprised of multiple independent systems. The new automated line will incorporate the company's proprietary ultrasonic coating technology.

The system is expected to ship during Sono-Tek's fiscal year 2028. The order signifies a major operational scale-up for the customer, which is moving from process development into high-volume manufacturing.

Customer Growth Validates Business Model

Sample IUX Markets – In-articleAd

The purchase was placed by a client that had previously used other Sono-Tek platforms to establish and validate its coating process, including a prior $820,000 production system. This progression from smaller systems to a large-scale, automated line highlights Sono-Tek's business model of supporting customers from development through to full production.

"This record production line order represents an important milestone for Sono-Tek and marks a major step forward in our relationship with this customer," said Steve Harshbarger, President and CEO of Sono-Tek. He noted the customer is now moving to a "substantially larger and more sophisticated automated manufacturing line designed for high-volume production."

Market Reaction

Following the news, shares of Sono-Tek rose 3.9% in premarket trading on Tuesday. For investors, the landmark order serves as a key validation of the company's technology and its strategy in the medical device coating sector, a primary component of its growth plans. The deal provides a tangible indicator of future revenue and the company's ability to scale with its clients.

Read next

More on Stocks
Back to latest news

LATEST